Currently, anti-CD19 CAR-T cells have demonstrated sustained remission rates in about 40% of chemotherapy-resistant DLBCL, high-grade B-cell lymphoma (HGBCL), and primary mediastinal B-cell lymphoma (PMBCL) patients who have not received previous treatment options. Here, CD19 is linked to B-cell non-Hodgkin lymphoma.